A Novel Strategy To Enhance T Cell-mediated Immunity To Vaccine Antigens
Funder
National Health and Medical Research Council
Funding Amount
$234,592.00
Summary
Globally there are about 33 million people living with HIV. The disease has already resulted in 23 million deaths and 2.5 million people are newly infected each year. Similarly, TB kills nearly 2 million people every year and infects about 1% of the worldÍs population every year. A vaccine is the best and also likely the only long-term solution for HIV/TB disease prevention. This research proposal looks at novel strategies to increase the efficacy of vaccines for diseases such as HIV/TB.
Development And Validation Of A Latent Tuberculosis Diagnostic
Funder
National Health and Medical Research Council
Funding Amount
$534,865.00
Summary
Globally, tuberculosis is a leading cause of death with 9.6 million new diagnoses in 2014. The diagnosis of latent TB infection is important, but is difficult to make because current assays are suboptimal. We have developed a very simple assay which detects responses to TB antigens by co-expression of two surface markers expressed by CD4+ T cells. We propose to develop this into a highly standardised kit for the diagnosis of TB with our commercial partner Cytognos.
Cancer Immunotherapy Utilizing A Novel Receptor For Programmed Cell Death-1 Ligand 2
Funder
National Health and Medical Research Council
Funding Amount
$577,857.00
Summary
Immuno-modulators utilize the patient’s own immune system to eliminate or slow the growth of cancerous cells. We have identified a novel immuno-modulator which could be a significant player in immune-modulation therapy for the treatment of cancer. We will use the development grant to develop a product which has significant potential to be the next generation treatment for cancer.
Novel NLRP3 Inhibitors For Steroid Resistant Asthma
Funder
National Health and Medical Research Council
Funding Amount
$927,117.00
Summary
Asthma causes 40,000 hospitalisations p.a. with 5-10% of asthmatics having severe steroid resistant asthma, a common and debilitating disease, where current treatments do not work. Effective therapies are urgently required. Based on our research, we have novel molecules showing high level of efficacy in models of severe steroid resistant asthma. These molecules will be further investigated to deliver a drug candidate for commercialisation within 3 years.
Pre-clinica Evaluation Of A Novel HIV-1 Vaccine Statrgy
Funder
National Health and Medical Research Council
Funding Amount
$528,440.00
Summary
Recently, we have designed two mucosal HIV vaccine strategies that temporary block hormone-like molecules IL-4/IL-13 at the vaccination site inducing excellent antibody and killer T cell immunity with protective efficacy in small animals. This project aims to evaluate the safety and efficacy of these novel HIV mucosal vaccines prior to clinical evaluation.
A vitamin-sized capsule, containing gas sensors, is to be fully developed for assessing the state of health and diagnosing the diseases relevant to gastrointestinal tract. The capsule travels along the tract, transmitting information about the gas species generated by the microorganisms of the gut, which is closely associated with the health of the human under surveillance. The information will be invaluable for diagnostics and adjusting the diet to mitigate and cure the diseases of the guts.